Loading...
Header Logo
Keywords
Last Name
Institution

KHANDAN KEYOMARSI

TitleProfessor
InstitutionMD Anderson
DepartmentExperimental Radiation Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, Carey JPW, Chen X, Eckols TK, Raghavendra AS, Ibrahim NK, Karuturi MS, Watowich SS, Sahin A, Tweardy DJ, Hunt KK, Tripathy D, Keyomarsi K. Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. Clin Cancer Res. 2019 Jul 01; 25(13):3996-4013. PMID: 30867218.
      View in: PubMed
    2. Caruso JA, Duong MT, Carey JPW, Hunt KK, Keyomarsi K. Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. Cancer Res. 2018 Oct 01; 78(19):5481-5491. PMID: 30194068.
      View in: PubMed
    3. Chen X, Low KH, Alexander A, Jiang Y, Karakas C, Hess KR, Carey JPW, Bui TN, Vijayaraghavan S, Evans KW, Yi M, Ellis DC, Cheung KL, Ellis IO, Fu S, Meric-Bernstam F, Hunt KK, Keyomarsi K. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Clin Cancer Res. 2018 Dec 15; 24(24):6594-6610. PMID: 30181387.
      View in: PubMed
    4. Fu S, Wang Y, Keyomarsi K, Meric-Bernstein F. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. Expert Opin Investig Drugs. 2018 09; 27(9):741-751. PMID: 30102076.
      View in: PubMed
    5. Carey JPW, Keyomarsi K. Leveraging MYC as a therapeutic treatment option for TNBC. Oncoscience. 2018 May; 5(5-6):137-139. PMID: 30035166.
      View in: PubMed
    6. Xi Y, Shi J, Li W, Tanaka K, Allton KL, Richardson D, Li J, Franco HL, Nagari A, Malladi VS, Coletta LD, Simper MS, Keyomarsi K, Shen J, Bedford MT, Shi X, Barton MC, Kraus WL, Li W, Dent SYR. Histone modification profiling in breast cancer cell lines highlights commonalities and differences among subtypes. BMC Genomics. 2018 02 20; 19(1):150. PMID: 29458327.
      View in: PubMed
    7. Vijayaraghavan S, Moulder S, Keyomarsi K, Layman RM. Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. Target Oncol. 2018 02; 13(1):21-38. PMID: 29218622.
      View in: PubMed
    8. Franco HL, Nagari A, Malladi VS, Li W, Xi Y, Richardson D, Allton KL, Tanaka K, Li J, Murakami S, Keyomarsi K, Bedford MT, Shi X, Li W, Barton MC, Dent SYR, Kraus WL. Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis. Genome Res. 2018 02; 28(2):159-170. PMID: 29273624.
      View in: PubMed
    9. Carey JPW, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Cancer Res. 2018 02 01; 78(3):742-757. PMID: 29180466.
      View in: PubMed
    10. Doostan I, Karakas C, Kohansal M, Low KH, Ellis MJ, Olson JA, Suman VJ, Hunt KK, Moulder SL, Keyomarsi K. Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. Clin Cancer Res. 2017 Dec 01; 23(23):7288-7300. PMID: 28947566.
      View in: PubMed
    11. Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK. Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. J Cancer. 2017; 8(11):2004-2009. PMID: 28819400.
      View in: PubMed
    12. Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, Raghavendra AS, Zhao Y, Bashour SI, Ibrahim NK, Karuturi M, Wang J, Winkler JD, Amaravadi RK, Hunt KK, Tripathy D, Keyomarsi K. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun. 2017 06 27; 8:15916. PMID: 28653662.
      View in: PubMed
    13. Francis AM, Alexander A, Liu Y, Vijayaraghavan S, Low KH, Yang D, Bui T, Somaiah N, Ravi V, Keyomarsi K, Hunt KK. CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. Mol Cancer Ther. 2017 09; 16(9):1751-1764. PMID: 28619757.
      View in: PubMed
    14. Alexander A, Karakas C, Chen X, Carey JP, Yi M, Bondy M, Thompson P, Cheung KL, Ellis IO, Gong Y, Krishnamurthy S, Alvarez RH, Ueno NT, Hunt KK, Keyomarsi K. Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget. 2017 Feb 28; 8(9):14897-14911. PMID: 28107181.
      View in: PubMed
    15. Hunt KK, Karakas C, Ha MJ, Biernacka A, Yi M, Sahin AA, Adjapong O, Hortobagyi GN, Bondy M, Thompson P, Cheung KL, Ellis IO, Bacus S, Symmans WF, Do KA, Keyomarsi K. Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clin Cancer Res. 2017 Jun 15; 23(12):2991-3002. PMID: 27881578.
      View in: PubMed
    16. Balaji K, Vijayaraghavan S, Diao L, Tong P, Fan Y, Carey JP, Bui TN, Warner S, Heymach JV, Hunt KK, Wang J, Byers LA, Keyomarsi K. AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Mol Cancer Res. 2017 01; 15(1):45-58. PMID: 27671334.
      View in: PubMed
    17. Karakas C, Biernacka A, Bui T, Sahin AA, Yi M, Akli S, Schafer J, Alexander A, Adjapong O, Hunt KK, Keyomarsi K. Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer. Am J Pathol. 2016 07; 186(7):1900-1912. PMID: 27182644.
      View in: PubMed
    18. JavanMoghadam S, Weihua Z, Hunt KK, Keyomarsi K. Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion. Cell Cycle. 2016 06 17; 15(12):1579-90. PMID: 27049344.
      View in: PubMed
    19. Lucenay KS, Doostan I, Karakas C, Bui T, Ding Z, Mills GB, Hunt KK, Keyomarsi K. Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. Cancer Res. 2016 04 15; 76(8):2406-18. PMID: 26928812.
      View in: PubMed
    20. Wang X, Jung YS, Jun S, Lee S, Wang W, Schneider A, Sun Oh Y, Lin SH, Park BJ, Chen J, Keyomarsi K, Park JI. PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness. Nat Commun. 2016 Feb 04; 7:10633. PMID: 26843124.
      View in: PubMed
    21. Jabbour-Leung NA, Chen X, Bui T, Jiang Y, Yang D, Vijayaraghavan S, McArthur MJ, Hunt KK, Keyomarsi K. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. Mol Cancer Ther. 2016 04; 15(4):593-607. PMID: 26826118.
      View in: PubMed
    22. Nanos-Webb A, Bui T, Karakas C, Zhang D, Carey JP, Mills GB, Hunt KK, Keyomarsi K. PKCiota promotes ovarian tumor progression through deregulation of cyclin E. Oncogene. 2016 05 12; 35(19):2428-40. PMID: 26279297.
      View in: PubMed
    23. Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res. 2015 Jun 25; 17:87. PMID: 26108797.
      View in: PubMed
    24. Mitri Z, Karakas C, Wei C, Briones B, Simmons H, Ibrahim N, Alvarez R, Murray JL, Keyomarsi K, Moulder S. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Invest New Drugs. 2015 Aug; 33(4):890-4. PMID: 25947565.
      View in: PubMed
    25. Pickering CR, Bast RC, Keyomarsi K. How will we recruit, train, and retain physicians and scientists to conduct translational cancer research? Cancer. 2015 Mar 15; 121(6):806-16. PMID: 25355050.
      View in: PubMed
    26. Caruso JA, Akli S, Pageon L, Hunt KK, Keyomarsi K. The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase. Oncogene. 2015 Jul; 34(27):3556-67. PMID: 25195861.
      View in: PubMed
    27. Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun. 2014 Mar 12; 5:3459. PMID: 24619206.
      View in: PubMed
    28. Caruso JA, Campana R, Wei C, Su CH, Hanks AM, Bornmann WG, Keyomarsi K. Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERa-positive breast cancer cells. Cell Cycle. 2014; 13(16):2587-99. PMID: 25486199.
      View in: PubMed
    29. Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res. 2014; 16(6):3417. PMID: 25551582.
      View in: PubMed
    30. Duong MT, Akli S, Macalou S, Biernacka A, Debeb BG, Yi M, Hunt KK, Keyomarsi K. Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells. Cancer Res. 2013 Sep 01; 73(17):5556-68. PMID: 23955388.
      View in: PubMed
    31. Murray MM, Bui T, Smith M, Bagheri-Yarmand R, Wingate H, Hunt KK, Keyomarsi K. Staurosporine is chemoprotective by inducing G1 arrest in a Chk1- and pRb-dependent manner. Carcinogenesis. 2013 Oct; 34(10):2244-52. PMID: 23722650.
      View in: PubMed
    32. Dutta P, Bui T, Bauckman KA, Keyomarsi K, Mills GB, Nanjundan M. EVI1 splice variants modulate functional responses in ovarian cancer cells. Mol Oncol. 2013 Jun; 7(3):647-68. PMID: 23517670.
      View in: PubMed
    33. Hunt KK, Wingate H, Yokota T, Liu Y, Mills GB, Zhang F, Fang B, Su CH, Zhang M, Yi M, Keyomarsi K. Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer. Breast Cancer Res. 2013 Jan 15; 15(1):R3. PMID: 23320734.
      View in: PubMed
    34. Akli S, Zhang XQ, Bondaruk J, Tucker SL, Czerniak PB, Benedict WF, Keyomarsi K. Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer. Cell Cycle. 2012 Apr 01; 11(7):1468-76. PMID: 22441703.
      View in: PubMed
    35. Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, Yi M, Mills GB, Hunt KK, Keyomarsi K. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet. 2012; 8(3):e1002538. PMID: 22479189.
      View in: PubMed
    36. Moghadam SJ, Hanks AM, Keyomarsi K. Breaking the cycle: An insight into the role of ERa in eukaryotic cell cycles. J Carcinog. 2011; 10:25. PMID: 22190867.
      View in: PubMed
    37. Nanos-Webb A, Jabbour NA, Multani AS, Wingate H, Oumata N, Galons H, Joseph B, Meijer L, Hunt KK, Keyomarsi K. Targeting low molecular weight cyclin E (LMW-E) in breast cancer. Breast Cancer Res Treat. 2012 Apr; 132(2):575-88. PMID: 21695458.
      View in: PubMed
    38. Valero V, Wingate H, Chada S, Liu Y, Palalon F, Mills G, Keyomarsi K, Hunt KK. MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells. Cancer Gene Ther. 2011 Jul; 18(7):510-9. PMID: 21546925.
      View in: PubMed
    39. Akli S, Van Pelt CS, Bui T, Meijer L, Keyomarsi K. Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. Cancer Res. 2011 May 01; 71(9):3377-86. PMID: 21385896.
      View in: PubMed
    40. Keyomarsi K, Efuet ET, Bui TN. Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells. Cell Biol Toxicol. 2011 Apr; 27(2):123-31. PMID: 20853140.
      View in: PubMed
    41. Caruso JA, Hunt KK, Keyomarsi K. The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer. Cancer Res. 2010 Sep 15; 70(18):7125-36. PMID: 20823156.
      View in: PubMed
    42. Bagheri-Yarmand R, Biernacka A, Hunt KK, Keyomarsi K. Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. Cancer Res. 2010 Jun 15; 70(12):5074-84. PMID: 20530685.
      View in: PubMed
    43. Bagheri-Yarmand R, Nanos-Webb A, Biernacka A, Bui T, Keyomarsi K. Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C. Cancer Res. 2010 Jun 15; 70(12):5085-95. PMID: 20530684.
      View in: PubMed
    44. Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, Biernacka A, Liu Y, Meijer L, Keyomarsi K, Hunt KK. A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene. 2010 Jul 08; 29(27):3896-907. PMID: 20453888.
      View in: PubMed
    45. Sun B, Wingate H, Swisher SG, Keyomarsi K, Hunt KK. Absence of pRb facilitates E2F1-induced apoptosis in breast cancer cells. Cell Cycle. 2010 Mar 15; 9(6):1122-30. PMID: 20237430.
      View in: PubMed
    46. Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin Cancer Res. 2010 Feb 15; 16(4):1179-90. PMID: 20145171.
      View in: PubMed
    47. Mull BB, Cox J, Bui T, Keyomarsi K. Post-translational modification and stability of low molecular weight cyclin E. Oncogene. 2009 Sep 03; 28(35):3167-76. PMID: 19561641.
      View in: PubMed
    48. Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin A, Valero V, Keyomarsi K, Gray JW, Borresen-Dale AL, Mills GB, Hennessy BT. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res. 2009 Jun 01; 15(11):3654-62. PMID: 19470724.
      View in: PubMed
    49. Lott ST, Chen N, Chandler DS, Yang Q, Wang L, Rodriguez M, Xie H, Balasenthil S, Buchholz TA, Sahin AA, Chaung K, Zhang B, Olufemi SE, Chen J, Adams H, Band V, El-Naggar AK, Frazier ML, Keyomarsi K, Hunt KK, Sen S, Haffty B, Hewitt SM, Krahe R, Killary AM. DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med. 2009 May 26; 6(5):e1000068. PMID: 19536326.
      View in: PubMed
    50. Wingate H, Puskas A, Duong M, Bui T, Richardson D, Liu Y, Tucker SL, Van Pelt C, Meijer L, Hunt K, Keyomarsi K. Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle. 2009 Apr 01; 8(7):1062-8. PMID: 19305161.
      View in: PubMed
    51. Delk NA, Hunt KK, Keyomarsi K. Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation. Cancer Res. 2009 Apr 01; 69(7):2817-25. PMID: 19318554.
      View in: PubMed
    52. Fearmonti RM, Keyomarsi K, Hunt KK. Biomarkers in neoadjuvant trials. Cancer Treat Res. 2009; 147:1-36. PMID: 21461824.
      View in: PubMed
    53. Shaye A, Sahin A, Hao Q, Hunt K, Keyomarsi K, Bedrosian I. Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Res Treat. 2009 Jun; 115(3):651-9. PMID: 19107593.
      View in: PubMed
    54. Keyomarsi K. A novel MCM-2 fragment with potential biological function in senescence. Cell Cycle. 2008 Nov 15; 7(22):3480. PMID: 19001846.
      View in: PubMed
    55. Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L, Keyomarsi K. Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res. 2008 Oct 01; 68(19):7966-74. PMID: 18829554.
      View in: PubMed
    56. Javanmoghadam-Kamrani S, Keyomarsi K. Synchronization of the cell cycle using lovastatin. Cell Cycle. 2008 Aug; 7(15):2434-40. PMID: 18677105.
      View in: PubMed
    57. Yokota T, Bui T, Liu Y, Yi M, Hunt KK, Keyomarsi K. Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT/enhancer binding protein beta. Cancer Res. 2007 Dec 01; 67(23):11272-83. PMID: 18056453.
      View in: PubMed
    58. von Holzen U, Pataer A, Raju U, Bocangel D, Vorburger SA, Liu Y, Lu X, Roth JA, Aggarwal BB, Barber GN, Keyomarsi K, Hunt KK, Swisher SG. The double-stranded RNA-activated protein kinase mediates radiation resistance in mouse embryo fibroblasts through nuclear factor kappaB and Akt activation. Clin Cancer Res. 2007 Oct 15; 13(20):6032-9. PMID: 17947465.
      View in: PubMed
    59. Bedrosian I, Lee C, Tucker SL, Palla SL, Lu K, Keyomarsi K. Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy. Clin Cancer Res. 2007 Aug 15; 13(16):4800-6. PMID: 17699858.
      View in: PubMed
    60. Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, Tucker S, Keyomarsi K. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res. 2007 Aug 01; 67(15):7212-22. PMID: 17671189.
      View in: PubMed
    61. Lambert L, Keyomarsi K. Cell cycle deregulation in breast cancer: insurmountable chemoresistance or Achilles' heel? Adv Exp Med Biol. 2007; 608:52-69. PMID: 17993232.
      View in: PubMed
    62. Barton MC, Akli S, Keyomarsi K. Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancer. J Cell Physiol. 2006 Dec; 209(3):686-94. PMID: 17001684.
      View in: PubMed
    63. McGahren-Murray M, Terry NH, Keyomarsi K. The differential staurosporine-mediated G1 arrest in normal versus tumor cells is dependent on the retinoblastoma protein. Cancer Res. 2006 Oct 01; 66(19):9744-53. PMID: 17018634.
      View in: PubMed
    64. Le XF, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K, Lee MH, Zhao J, Bast RC. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway. Cell Cycle. 2006 Aug; 5(15):1654-61. PMID: 16861913.
      View in: PubMed
    65. Efuet ET, Keyomarsi K. Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome. Cancer Res. 2006 Jan 15; 66(2):1040-51. PMID: 16424040.
      View in: PubMed
    66. Tez M, Tez S. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 2005 Oct 15; 104(8):1779-80; author reply 1780. PMID: 16104028.
      View in: PubMed
    67. Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP, Kango-Singh M, Lu KH, Warneke CL, Atkinson EN, Bedrosian I, Keyomarsi K, Kuo WL, Gray JW, Yin JC, Liu J, Halder G, Mills GB. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A. 2005 Aug 30; 102(35):12519-24. PMID: 16116079.
      View in: PubMed
    68. Hunt KK, Keyomarsi K. Cyclin E as a prognostic and predictive marker in breast cancer. Semin Cancer Biol. 2005 Aug; 15(4):319-26. PMID: 16043362.
      View in: PubMed
    69. Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem. 2005 Apr 15; 280(15):15148-57. PMID: 15708847.
      View in: PubMed
    70. Bales E, Mills L, Milam N, McGahren-Murray M, Bandyopadhyay D, Chen D, Reed JA, Timchenko N, van den Oord JJ, Bar-Eli M, Keyomarsi K, Medrano EE. The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res. 2005 Feb 01; 65(3):692-7. PMID: 15705861.
      View in: PubMed
    71. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Jul 15; 59(4):928-42. PMID: 15234026.
      View in: PubMed
    72. Akli S, Keyomarsi K. Low-molecular-weight cyclin E: the missing link between biology and clinical outcome. Breast Cancer Res. 2004; 6(5):188-91. PMID: 15318923.
      View in: PubMed
    73. Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res. 2004 May 01; 64(9):3198-208. PMID: 15126360.
      View in: PubMed
    74. Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene. 2004 Apr 08; 23(15):2648-57. PMID: 15007381.
      View in: PubMed
    75. Harwell RM, Mull BB, Porter DC, Keyomarsi K. Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells. J Biol Chem. 2004 Mar 26; 279(13):12695-705. PMID: 14701826.
      View in: PubMed
    76. Wingate H, Bedrosian I, Akli S, Keyomarsi K. The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle. 2003 Sep-Oct; 2(5):461-6. PMID: 12963845.
      View in: PubMed
    77. Akli S, Keyomarsi K. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther. 2003 Jul-Aug; 2(4 Suppl 1):S38-47. PMID: 14508079.
      View in: PubMed
    78. Rabinowitz I. Cyclin E in breast cancer. N Engl J Med. 2003 Mar 13; 348(11):1063-4; author reply 1063-4. PMID: 12638587.
      View in: PubMed
    79. Keyomarsi K, Tucker SL, Bedrosian I. Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. Nat Med. 2003 Feb; 9(2):152. PMID: 12563321.
      View in: PubMed
    80. Keyomarsi K, Pardee AB. Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents. Prog Cell Cycle Res. 2003; 5:527-32. PMID: 14593747.
      View in: PubMed
    81. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS. Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002 Nov 14; 347(20):1566-75. PMID: 12432043.
      View in: PubMed
    82. Blagosklonny MV, Campisi J, Keyomarsi K, Medrano EE. No restriction points in life and science. Cell Cycle. 2002 Mar-Apr; 1(2):100-2. PMID: 12429915.
      View in: PubMed
    83. Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S, Keyomarsi K. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol. 2001 Sep; 21(18):6254-69. PMID: 11509668.
      View in: PubMed
    84. Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW, Elledge SJ. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science. 2001 Oct 05; 294(5540):173-7. PMID: 11533444.
      View in: PubMed
    85. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene. 2001 Jan 11; 20(2):147-55. PMID: 11313944.
      View in: PubMed
    86. Chen X, Lowe M, Herliczek T, Hall MJ, Danes C, Lawrence DA, Keyomarsi K. Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G(1) arrest. J Natl Cancer Inst. 2000 Dec 20; 92(24):1999-2008. PMID: 11121462.
      View in: PubMed
    87. Porter DC, Keyomarsi K. Novel splice variants of cyclin E with altered substrate specificity. Nucleic Acids Res. 2000 Dec 01; 28(23):E101. PMID: 11095697.
      View in: PubMed
    88. Chen X, Danes C, Lowe M, Herliczek TW, Keyomarsi K. Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells. J Natl Cancer Inst. 2000 Sep 06; 92(17):1403-13. PMID: 10974076.
      View in: PubMed
    89. Fasco MJ, Keyomarsi K, Arcaro KF, Gierthy JF. Expression of an estrogen receptor alpha variant protein in cell lines and tumors. Mol Cell Endocrinol. 2000 Aug 30; 166(2):156-69. PMID: 11203301.
      View in: PubMed
    90. Robertson KD, Keyomarsi K, Gonzales FA, Velicescu M, Jones PA. Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells. Nucleic Acids Res. 2000 May 15; 28(10):2108-13. PMID: 10773079.
      View in: PubMed
    91. Fasco MJ, Keyomarsi K, Arcaro KF, Gierthy JF. Expression of an estrogen receptor alpha variant protein in cell lines and tumors. Mol Cell Endocrinol. 2000 Apr 25; 162(1-2):167-80. PMID: 10854710.
      View in: PubMed
    92. Harwell RM, Porter DC, Danes C, Keyomarsi K. Processing of cyclin E differs between normal and tumor breast cells. Cancer Res. 2000 Jan 15; 60(2):481-9. PMID: 10667604.
      View in: PubMed
    93. Rao S, Gray-Bablin J, Herliczek TW, Keyomarsi K. The biphasic induction of p21 and p27 in breast cancer cells by modulators of cAMP is posttranscriptionally regulated and independent of the PKA pathway. Exp Cell Res. 1999 Oct 10; 252(1):211-23. PMID: 10502413.
      View in: PubMed
    94. Chen X, Lowe M, Keyomarsi K. UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent. Oncogene. 1999 Oct 07; 18(41):5691-702. PMID: 10577141.
      View in: PubMed
    95. Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A. 1999 Jul 06; 96(14):7797-802. PMID: 10393901.
      View in: PubMed
    96. Rao S, Lowe M, Herliczek TW, Keyomarsi K. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene. 1998 Nov 05; 17(18):2393-402. PMID: 9811471.
      View in: PubMed
    97. Gray-Bablin J, Rao S, Keyomarsi K. Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Res. 1997 Feb 15; 57(4):604-9. PMID: 9044834.
      View in: PubMed
    98. Stover PJ, Chen LH, Suh JR, Stover DM, Keyomarsi K, Shane B. Molecular cloning, characterization, and regulation of the human mitochondrial serine hydroxymethyltransferase gene. J Biol Chem. 1997 Jan 17; 272(3):1842-8. PMID: 8999870.
      View in: PubMed
    99. Keyomarsi K, Herliczek TW. The role of cyclin E in cell proliferation, development and cancer. Prog Cell Cycle Res. 1997; 3:171-91. PMID: 9552414.
      View in: PubMed
    100. Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, DeCaprio JA, Keyomarsi K. Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci U S A. 1996 Dec 24; 93(26):15215-20. PMID: 8986790.
      View in: PubMed
    101. Huang Z, Fasco MJ, Figge HL, Keyomarsi K, Kaminsky LS. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos. 1996 Aug; 24(8):899-905. PMID: 8869826.
      View in: PubMed
    102. Bacus SS, Yarden Y, Oren M, Chin DM, Lyass L, Zelnick CR, Kazarov A, Toyofuku W, Gray-Bablin J, Beerli RR, Hynes NE, Nikiforov M, Haffner R, Gudkov A, Keyomarsi K. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. Oncogene. 1996 Jun 20; 12(12):2535-47. PMID: 8700512.
      View in: PubMed
    103. Dou QP, Pardee AB, Keyomarsi K. Cyclin E -- a better prognostic marker for breast cancer than cyclin D? Nat Med. 1996 Mar; 2(3):254. PMID: 8612208.
      View in: PubMed
    104. Keyomarsi K, Conte D, Toyofuku W, Fox MP. Deregulation of cyclin E in breast cancer. Oncogene. 1995 Sep 07; 11(5):941-50. PMID: 7675453.
      View in: PubMed
    105. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E, et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell. 1995 Apr; 6(4):387-400. PMID: 7626805.
      View in: PubMed
    106. Rosowsky A, Bader H, Wright JE, Keyomarsi K, Matherly LH. Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin. J Med Chem. 1994 Jul 08; 37(14):2167-74. PMID: 8035423.
      View in: PubMed
    107. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res. 1994 Jan 15; 54(2):380-5. PMID: 7903908.
      View in: PubMed
    108. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993 Nov 19; 75(4):805-16. PMID: 8242751.
      View in: PubMed
    109. Keyomarsi K, Samet J, Molnar G, Pardee AB. The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme. J Biol Chem. 1993 Jul 15; 268(20):15142-9. PMID: 8325888.
      View in: PubMed
    110. Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A. 1993 Feb 01; 90(3):1112-6. PMID: 8430082.
      View in: PubMed
    111. Liang P, Averboukh L, Keyomarsi K, Sager R, Pardee AB. Differential display and cloning of messenger RNAs from human breast cancer versus mammary epithelial cells. Cancer Res. 1992 Dec 15; 52(24):6966-8. PMID: 1458489.
      View in: PubMed
    112. Motokura T, Keyomarsi K, Kronenberg HM, Arnold A. Cloning and characterization of human cyclin D3, a cDNA closely related in sequence to the PRAD1/cyclin D1 proto-oncogene. J Biol Chem. 1992 Oct 05; 267(28):20412-5. PMID: 1383201.
      View in: PubMed
    113. Lee SW, Tomasetto C, Paul D, Keyomarsi K, Sager R. Transcriptional downregulation of gap-junction proteins blocks junctional communication in human mammary tumor cell lines. J Cell Biol. 1992 Sep; 118(5):1213-21. PMID: 1324944.
      View in: PubMed
    114. Pardee AB, Keyomarsi K. Modification of cell proliferation with inhibitors. Curr Opin Cell Biol. 1992 Apr; 4(2):186-91. PMID: 1376129.
      View in: PubMed
    115. Lee SW, Tomasetto C, Swisshelm K, Keyomarsi K, Sager R. Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment. Proc Natl Acad Sci U S A. 1992 Mar 15; 89(6):2504-8. PMID: 1372446.
      View in: PubMed
    116. Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 1991 Jul 01; 51(13):3602-9. PMID: 1711413.
      View in: PubMed
    117. Fridovich-Keil JL, Hansen LJ, Keyomarsi K, Pardee AB. Progression through the cell cycle: an overview. Am Rev Respir Dis. 1990 Dec; 142(6 Pt 2):S3-6. PMID: 2252273.
      View in: PubMed
    118. Keyomarsi K, Moran RG. Quinazoline folate analogs inhibit the catalytic activity of thymidylate synthase but allow binding of 5-fluorodeoxyuridylate. J Biol Chem. 1990 Nov 05; 265(31):19163-9. PMID: 2146271.
      View in: PubMed
    119. Geller AI, Keyomarsi K, Bryan J, Pardee AB. An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology. Proc Natl Acad Sci U S A. 1990 Nov; 87(22):8950-4. PMID: 2174168.
      View in: PubMed
    120. Keyomarsi K, Moran RG. Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells. J Biol Chem. 1988 Oct 05; 263(28):14402-9. PMID: 2971656.
      View in: PubMed
    121. Moran RG, Keyomarsi K, Patel R. Tumor cell responses to inhibition of thymidylate synthase. Adv Exp Med Biol. 1988; 244:71-83. PMID: 2977717.
      View in: PubMed
    122. Mahnovski V, Cheng MH, Lipsey AI, Keyomarsi K. Drugs in blood donors. Clin Chem. 1987 Jan; 33(1):189. PMID: 3802478.
      View in: PubMed
    123. Moran RG, Keyomarsi K. Biochemical rationale for the synergism of 5-fluorouracil and folinic acid. NCI Monogr. 1987; (5):159-63. PMID: 2963229.
      View in: PubMed
    124. Keyomarsi K, Moran RG. Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res. 1986 Oct; 46(10):5229-35. PMID: 2944577.
      View in: PubMed
    125. Moran RG, Keyomarsi K, Colman PD. Preparation of (6S)-5-formyltetrahydrofolate labeled at high specific activity with 14C and 3H. Methods Enzymol. 1986; 122:309-12. PMID: 3517564.
      View in: PubMed
    126. PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness. Nature Communications. 7.
    127. Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion. Cell Cycle. 1-12.
    128. Biomarkers in neoadjuvant trials. 125-160.
    129. Erratum. Molecular and Cellular Endocrinology. 166:155-169.
    130. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Research. 16.
    131. Cyclin e amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Breast Diseases. 22:266-267.
    132. The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase. Oncogene. 34:3556-3567.
    133. Cyclin e associates with the lipogenic enzyme ATP-citrate lyase to enable malignant growth of breast cancer cells. Cancer Research. 76:2406-2418.
    134. AXL inhibition suppresses the DNA damage response and sensitizes cells to PARP inhibition in multiple cancers. Molecular Cancer Research. 15:45-58.
    135. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Investigational New Drugs.
    136. Synchronization of mammalian cells by Lovastatin. Methods in Cell Science. 18:109-114.
    137. Targeting the Cell Cycle in Breast Cancer. Breast Diseases. 27:256-260.
    138. Erratum to. Breast Cancer Research. 17.
    139. Understanding the Biology of Cancer. 101-122.
    140. PKCiota promotes ovarian tumor progression through deregulation of cyclin E. Oncogene.
    141. Sequential combination therapy of CDK inhibition and doxorubicin is synthetically lethal in p53-mutant Triple-negative breast cancer. Molecular Cancer Therapeutics. 15:593-607.
    KEYOMARSI's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description